New Enterade Clinical Study Demonstrates Fewer Stopped Treatments and Lower GI Side Effects for Cancer Patients
Baptist Health Cancer Care Abstract to be presented at Oncology Nursing Society Annual Symposium
Excerpt from the Press Release:
NORWOOD, Mass., April 27, 2023 /PRNewswire/ — Entrinsic Bioscience is pleased to announce the upcoming poster session on the role of Enterade® Advanced Oncology Formula in reducing adverse gastrointestinal side effects for patients undergoing cancer treatment. The event will showcase the preliminary results of an ongoing clinical study that is being conducted by a team of researchers and practitioners from Baptist Health Louisville Cancer Care in Louisville, Kentucky.
The abstract, titled “Evaluating the Use of an Amino Acid Food to Alleviate Chemotherapy Induced Toxicity in Cancer Patients,” will be presented during the Oncology Nursing Society Annual Symposium held in San Antonio, Texas from April 27-30. The presentation of this research on April 27th will show promising results of Enterade in managing the side effects typically experienced by patients undergoing cancer therapies or treatments. Significant cost savings may also be realized by organizations that order Enterade for patients receiving chemotherapy regimens that are likely to cause GI symptoms by avoiding unplanned visits, IV hydration and hospitalizations.
This study highlights Enterade’s potential to transform the landscape of cancer care and provide valuable insights for researchers and practitioners alike.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?